234 related articles for article (PubMed ID: 15974896)
1. Cholinesterases: roles in the brain during health and disease.
Ballard CG; Greig NH; Guillozet-Bongaarts AL; Enz A; Darvesh S
Curr Alzheimer Res; 2005 Jul; 2(3):307-18. PubMed ID: 15974896
[TBL] [Abstract][Full Text] [Related]
2. Targeting acetylcholinesterase and butyrylcholinesterase in dementia.
Lane RM; Potkin SG; Enz A
Int J Neuropsychopharmacol; 2006 Feb; 9(1):101-24. PubMed ID: 16083515
[TBL] [Abstract][Full Text] [Related]
3. Cholinesterases: new roles in brain function and in Alzheimer's disease.
Giacobini E
Neurochem Res; 2003 Apr; 28(3-4):515-22. PubMed ID: 12675140
[TBL] [Abstract][Full Text] [Related]
4. Selective inhibitors of butyrylcholinesterase: a valid alternative for therapy of Alzheimer's disease?
Giacobini E
Drugs Aging; 2001; 18(12):891-8. PubMed ID: 11888344
[TBL] [Abstract][Full Text] [Related]
5. A new therapeutic target in Alzheimer's disease treatment: attention to butyrylcholinesterase.
Greig NH; Utsuki T; Yu Q; Zhu X; Holloway HW; Perry T; Lee B; Ingram DK; Lahiri DK
Curr Med Res Opin; 2001; 17(3):159-65. PubMed ID: 11900310
[TBL] [Abstract][Full Text] [Related]
6. The interactions of azure B, a metabolite of methylene blue, with acetylcholinesterase and butyrylcholinesterase.
Petzer A; Harvey BH; Petzer JP
Toxicol Appl Pharmacol; 2014 Feb; 274(3):488-93. PubMed ID: 24161345
[TBL] [Abstract][Full Text] [Related]
7. Cholinesterase inhibitors: new roles and therapeutic alternatives.
Giacobini E
Pharmacol Res; 2004 Oct; 50(4):433-40. PubMed ID: 15304240
[TBL] [Abstract][Full Text] [Related]
8. Acetylcholinesterase and butyrylcholinesterase activities in cerebrospinal fluid from different levels of the neuraxis of patients with dementia of the Alzheimer type.
Appleyard ME; McDonald B
J Neurol Neurosurg Psychiatry; 1992 Nov; 55(11):1074-8. PubMed ID: 1469405
[TBL] [Abstract][Full Text] [Related]
9. Cholinesterase inhibitors proposed for treating dementia in Alzheimer's disease: selectivity toward human brain acetylcholinesterase compared with butyrylcholinesterase.
Pacheco G; Palacios-Esquivel R; Moss DE
J Pharmacol Exp Ther; 1995 Aug; 274(2):767-70. PubMed ID: 7636741
[TBL] [Abstract][Full Text] [Related]
10. Functional variability in butyrylcholinesterase activity regulates intrathecal cytokine and astroglial biomarker profiles in patients with Alzheimer's disease.
Darreh-Shori T; Vijayaraghavan S; Aeinehband S; Piehl F; Lindblom RP; Nilsson B; Ekdahl KN; Långström B; Almkvist O; Nordberg A
Neurobiol Aging; 2013 Nov; 34(11):2465-81. PubMed ID: 23759148
[TBL] [Abstract][Full Text] [Related]
11. 1,4-Substituted 4-(1H)-pyridylene-hydrazone-type inhibitors of AChE, BuChE, and amyloid-β aggregation crossing the blood-brain barrier.
Prinz M; Parlar S; Bayraktar G; Alptüzün V; Erciyas E; Fallarero A; Karlsson D; Vuorela P; Burek M; Förster C; Turunc E; Armagan G; Yalcin A; Schiller C; Leuner K; Krug M; Sotriffer CA; Holzgrabe U
Eur J Pharm Sci; 2013 Jul; 49(4):603-13. PubMed ID: 23643737
[TBL] [Abstract][Full Text] [Related]
12. Rivastigmine: the advantages of dual inhibition of acetylcholinesterase and butyrylcholinesterase and its role in subcortical vascular dementia and Parkinson's disease dementia.
Kandiah N; Pai MC; Senanarong V; Looi I; Ampil E; Park KW; Karanam AK; Christopher S
Clin Interv Aging; 2017; 12():697-707. PubMed ID: 28458525
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of acetyl- and butyryl-cholinesterase in the cerebrospinal fluid of patients with Alzheimer's disease by rivastigmine: correlation with cognitive benefit.
Giacobini E; Spiegel R; Enz A; Veroff AE; Cutler NR
J Neural Transm (Vienna); 2002 Jul; 109(7-8):1053-65. PubMed ID: 12111443
[TBL] [Abstract][Full Text] [Related]
14. Rationale for diagnosing deficiency of ChEs and for applying exogenous HuChEs to the treatment of diseases.
Shen ZX
Med Hypotheses; 2008; 70(1):43-51. PubMed ID: 17587508
[TBL] [Abstract][Full Text] [Related]
15. [Cholinesterases and their importance in the etiology, diagnosis and therapy of Alzheimer's disease].
Patocka J; Strunecká A; Rípová D
Cesk Fysiol; 2001 Feb; 50(1):4-10. PubMed ID: 11268561
[TBL] [Abstract][Full Text] [Related]
16. Tea polyphenols as multi-target therapeutics for Alzheimer's disease: An in silico study.
Mazumder MK; Choudhury S
Med Hypotheses; 2019 Apr; 125():94-99. PubMed ID: 30902161
[TBL] [Abstract][Full Text] [Related]
17. On functions of cholinesterases during embryonic development.
Paraoanu LE; Steinert G; Klaczinski J; Becker-Röck M; Bytyqi A; Layer PG
J Mol Neurosci; 2006; 30(1-2):201-4. PubMed ID: 17192676
[TBL] [Abstract][Full Text] [Related]
18. Novel cholinesterase inhibitors as future effective drugs for the treatment of Alzheimer's disease.
Martinez A; Castro A
Expert Opin Investig Drugs; 2006 Jan; 15(1):1-12. PubMed ID: 16370929
[TBL] [Abstract][Full Text] [Related]
19. Genetic predisposition to adverse consequences of anti-cholinesterases in 'atypical' BCHE carriers.
Loewenstein-Lichtenstein Y; Schwarz M; Glick D; Nørgaard-Pedersen B; Zakut H; Soreq H
Nat Med; 1995 Oct; 1(10):1082-5. PubMed ID: 7489367
[TBL] [Abstract][Full Text] [Related]
20. Glycosylation of acetylcholinesterase and butyrylcholinesterase changes as a function of the duration of Alzheimer's disease.
Sáez-Valero J; Fodero LR; Sjögren M; Andreasen N; Amici S; Gallai V; Vanderstichele H; Vanmechelen E; Parnetti L; Blennow K; Small DH
J Neurosci Res; 2003 May; 72(4):520-6. PubMed ID: 12704813
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
